Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rufinamide on Quizartinib Pharmacokinetics
NCT06740825Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at Day 33, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at Day 33 and 1 more. Started Oct 2024; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06740825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740825.